Physician profile
Mark Haeberle
NPI 1558650291
$3,484.26
in general payments reported to CMS, 2019-2025
21 companies · $450 in 2025
The $450 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $629 · 2020: $202 · 2021: $495 · 2022: $438 · 2023: $599 · 2024: $671 · 2025: $450.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,520 · Education: $200.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,520.23 |
| Education | $199.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $833.45 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $553.25 | 2019-2025 | |
| Janssen Biotech, INC. | $515.87 | 2021-2025 | Tremfya |
| Regeneron Healthcare Solutions, INC. | $329.80 | 2020-2024 | Dupixent, Libtayo |
| Sun Pharmaceutical Industries INC. | $308.25 | 2019-2025 | Odomzo, Blu-U |
| Genzyme Corporation | $136.12 | 2019-2024 | |
| Ucb, INC. | $111.91 | 2019-2025 | Bimzelx |
| Pfizer INC. | $111.70 | 2019-2025 | |
| Leo Pharma INC. | $92.08 | 2019-2023 | Adbry |
| E.R. Squibb & Sons, L.L.C. | $91.28 | 2023-2025 | Sotyktu |
| Lilly USA, LLC | $82.01 | 2019-2022 | |
| Genentech USA, INC. | $56.92 | 2019-2022 | |
| Galderma Laboratories, L.P. | $56.75 | 2021-2024 | Aklief |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $50.26 | 2019-2023 | Jublia |
| Organogenesis INC. | $36.26 | 2023-2024 | Puraply |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Arcutis Biotherapeutics, INC. | $34.20 | 2023-2025 | Zoryve |
| Mayne Pharma Commercial LLC | $24.59 | 2025 | |
| Biofrontera INC. | $15.86 | 2019 | |
| Convatec INC. | $15.47 | 2024 | |
| Amgen INC. | $14.93 | 2019 | |
| Dermira, INC. | $13.30 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Haeberle listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.